Skip to main content

Advertisement

Table 2 Univariate analysis of overall survival (OS) and recurrence-free survival (RFS) of the 285 HCC patients

From: Transcatheter arterial chemoembolization combined with CT-guided percutaneous thermal ablation versus hepatectomy in the treatment of hepatocellular carcinoma

Variable Number of patients OS (months) P RFS (months) P
Age    0.879   0.921
  <65 years 238 79.4 ± 4.6   72.4 ± 4.6  
  ≥65 years 47 77.9 ± 8.6   73.4 ± 9.4  
Sex    0.163   0.141
  Male 262 83.0 ± 4.3   76.4 ± 4.2  
  Female 23 54.0 ± 7.2   47.5 ± 8.1  
Cirrhosis    0.911   0.806
  Yes 250 80.4 ± 4.4   73.7 ± 4.3  
  No 35 67.6 ± 8.3   64.1 ± 8.8  
Treatment allocation    0.012   0.004
  Combinationa 137 91.2 ± 6.1   84.1 ± 6.0  
  Surgery 148 61.7 ± 3.8   57.1 ± 4.3  
Tumor number    <0.001   <0.001
  1 128 80.4 ± 5.0   66.7 ± 3.9  
  2 93 73.3 ± 6.8   69.8 ± 7.2  
  3 49 82.2 ± 9.5   75.3 ± 8.6  
  4 15 31.8 ± 10.0   26.6 ± 7.7  
CA19-9    0.088   0.093
  Positive 113 71.0 ± 5.8   68.0 ± 6.1  
  Negative 172 84.1 ± 5.5   74.1 ± 4.9  
Alpha fetoprotein    0.004   0.002
  ≥400 ng/mL 79 60.6 ± 6.7   56.6 ± 7.1  
  <400 ng/mL 206 87.2 ± 4.8   79.2 ± 4.5  
Albumin    0.003   0.014
  ≥40 g/L 174 87.4 ± 5.4   76.8 ± 4.9  
  <40 g/L 111 65.3 ± 5.9   62.5 ± 6.2  
Prothrombin time    0.018   0.011
  ≤13.5 s 217 85.0 ± 4.9   78.2 ± 4.8  
  >13.5 s 68 63.0 ± 6.8   58.2 ± 7.4  
Platelet count    0.417   0.604
  ≥100 × 109/L 200 82.5 ± 4.9   74.0 ± 4.6  
  <100 × 109/L 85 72.1 ± 6.9   9.0 ± 7.5  
Hemoglobin    0.456   0.239
  ≥120 × 1012/L 247 81.6 ± 4.4   75.5 ± 4.2  
  <120 × 1012/L 38 67.9 ± 9.3   51.6 ± 7.9  
Maximal tumor size    0.009   0.004
  ≤3 cm 130 95.0 ± 5.4   88.2 ± 5.3  
  >3 cm 155 65.8 ± 4.8   56.1 ± 4.3  
Hypersplenism    0.941   0.668
  Yes 144 79.4 ± 6.2   73.6 ± 5.9  
  No 141 76.0 ± 5.0   71.8 ± 5.4  
  1. All values are presented as mean ± standard deviation. aCombination treatment includes ablation and hepatectomy.